View Older Stories View More Recent Stories
-
Revolution Lighting (RVLT) Prices 8M Common Offering at $1.25/Share
-
Trina Solar (TSL) Investors are Seeking More Visibility - Roth Capital
-
Revolution Lighting (RVLT) Announces Common Stock Offering
-
Streetinsider.com's Hot Lunchtime Reads 11/20: (LB) (AMZN) (REGN) (GS) (FB)
-
Regeneron's (REGN) Dupilumab Receives FDA Breakthrough Designation; Roth Capital Comments
-
Roth Updates Model on Trina Solar (TSL) Following Oct. Capital Raise; Affirms 'Buy' Rating
-
Roth Cuts PT on RGS Energy (RGSE) to 80c Following Q3 Miss, Lack of Guidance
-
Roth Comments on Regeneron (REGN) Following ODYSSEY Update at AHA (SNY)
-
Roth is Buyer of JA Solar (JASO) Following Q3 Results; Affirms 'Buy' Rating
-
Significant Partnership Could be in Store for Can-Fite (CANF) - Roth
-
Roth Capital Starts New Gold (NGD) at Neutral
-
Roth Capital Positive on Galena (GALE) Following Quick Enrollment of GALE-401 Phase 2
-
Roth Capital Comments on Keryx (KERX) Following KOL Panel; Affirms 'Buy' Rating
-
Notable Analyst Rating Changes 11/17: (MTG) (PSX) (CHK) Upgraded; (NOK) (ODP) (WTSL) Downgraded
-
Pre-Open Stock Movers 11/17: (CLDX) (BHI) (AGN) Higher; (DWA) (GSAT) (HAL) Lower (more...)
-
Roth Capital Lifts PT on Celldex (CLDX) to $43 Following Phase 2 ReACT Presentation
-
Roth Capital Downgrades Hecla Mining (HL) to Neutral
-
Roth Remains Positive on ImmunoCellular (IMUC) Following ICT-107 Phase 2 Presentation at SNO
-
Canadian Solar's (CSIQ) Margin Guidance Spooks Investors, Buy Industry Position Remains Strong - Roth
-
Roth Cuts PT on Plug Power (PLUG) to $4 Following 'Largely Disappointing' Q3 Report
-
Roth Trims Price Target on Concert (CNCE) to $21; CTP-354 Phase II Delayed on Toxicity Signal
-
Roth Capital Upgrades Dendreon (DNDN) to Neutral
-
Roth Comments on Galena (GALE) Following Initiation of Herceptin Combo Trial
-
Roth Positive on TG Therapeutics (TGTX) Following Q3 Results; Expects Strong ASH Showing
-
The Joint Corp (JYNT) IPO Opens Slightly Higher
-
Roth Affirms Sunesis (SNSS) at 'Neutral'; ASH Presentations May Help Clear Cloudy Outlook
-
Sage (SAGE) SRSE Data is Positive for Ligand Pharma (LGND) - Roth
-
Roth Capital Downgrades Planar Systems (PLNR) to Neutral
-
Roth Capital Upgrades ICU Medical (ICUI) to Buy
-
Roth Affirms Curis (CRIS) at 'Buy' Following Q3 Report, Update; Pipeline Progress is Encouraging
-
Streetinsider.com's Hot Lunchtime Reads 11/10: (TWTR) (HIMX) (SVU) (AGU)
-
Roth Capital 'Encouraged' by PoC Data from Celldex's (CLDX) Varlilumab Phase 1
-
Roth Capital Trims PT on Clean Diesel Technologies (CDTI) to $3.50 Following Mixed Q3 Results
-
Roth Capital Slashes PT on Dendreon (DNDN) to 15c; Sale Unlikely Following Ch. 11 Filing
-
CTI BioPharma (CTIC) Prices $35M Offering of Convertible Preferred Stock
-
Roth Capital Positive on TG Therapeutics (TGTX) Following Publication of ASH Abstracts
-
SolarCity (SCTY) Still 'Buy'-Rated at Roth; Would Likely Withstand Peer Pricing Pressure
-
Roth Capital Positive on Synta (SNTA) Following Q3 Results; Focus Remains on Ganetespib Phase III GALAXY-2
-
Roth Capital Remains Positive on Keryx (KERX) Following Q3 Results, Update
-
Synta's (SNTA) Ganetespib Could See Extra Exclusivity Following FDA Meeting - Roth
-
Roth Cap Remains Positive on Galena Biopharma (GALE) Following Q3 Results, Update
-
Roth Capital Starts Ballard Power Systems (BLDP) at Buy
-
Roth 'Encouraged' by Initial BL-8040 Safety, Pharmacodynamic Data; Maintains BioLineRx (BLRX) at 'Buy'
-
Roth Capital Starts Hyperion Therapeutics (HPTX) at Buy
-
Roth Capital Downgrades GP Strategies (GPX) to Neutral
-
Notable Analyst Rating Changes 10/31: (AXTI) (MPW) (ACHC) Upgraded; (ARR) (AVP) (TASR) Downgraded
-
UPDATE: Roth Capital Starts Daqo New Energy (DQ) at Buy
-
Peregrine's (PPHM) Phase Ib IST of Bavituximab Important Progress in Development as NSCLC Treatment - Roth
-
Roth Affirms GenVec (GNVC) at 'Buy'; Novartis Partnership is Entering 'Prime Time'
-
Roth Capital Maintains Synta Pharma (SNTA) at 'Buy; Has Initial Meeting with CEO Whitaker

